NCT03093402已完成2 期
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
National Institute of Allergy and Infectious Diseases (NIAID)30 个研究点 分布在 1 个国家目标入组 109 人开始时间: 2017年12月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 109
- 试验地点
- 30
- 主要终点
- Improvement in the Maximum Daily NRS-Pain Score at Day 84
研究概览
简要总结
The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE).
- One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body's normal processes, to resolve innate immune responses without immunosuppression.
- Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses) or, placebo, for 84 days and will continue to be followed for an additional 28 days. Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then every 4 weeks three times, for a total of six visits.
- The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fulfills the updated American College of Rheumatology (ACR) 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus;
- •At least 3 months of treatment with an anti-malarial drug such as hydroxychloroquine or a history of intolerance, contraindication, or unwillingness to take an anti-malarial drug;
- •Meets the Safety of Estrogen in Lupus: National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) definition of arthritis (Petri et al., 1999) or mild/moderate arthritis or tendonitis scored as a BILAG B on the updated BILAG 2004;
- •Seven-day average of maximum of daily pain Numerical Rating Scale (NRS) scores ≥ 4 out of 10;
- •Overlap with polymyositis, systemic sclerosis, Sjögren's syndrome, or rheumatoid arthritis is allowed, if, in the site investigator's judgment, the predominant clinical features are those of Systemic Lupus Erythematosus (SLE);
- •Not expected by the site investigator to require a change in potential disease- modifying treatments for SLE from Screening through Visit 6 (Day 112);
- •Willing to not start nor stop any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or potential disease-modifying medications or supplements for SLE from Screening through Visit 6 (Day 112), unless a change is recommended by the site investigator or other treating physicians;
- •Willing not to use any legal or illegal cannabinoids, including Food and Drug Administration (FDA)-approved cannabinoids or cannabinoid-mimic drugs, or any illegal substance of abuse from Screening through Visit 6 (Day 112);
- •If a woman of child-bearing potential, willing to use one of the highly effective (failure rate < 1% per year) birth control method from Screening through Visit 6 (Day 112) or for 28 ± 3 days after the last dose of study product; and
- •Willing to follow instructions, complete study procedures and attend study visits as required by this protocol.
排除标准
- •Severe or unstable Systemic lupus erythematosus (SLE), such as any one of the following:
- •A British Isles Lupus Activity Group (BILAG) A score in one or more BILAG domains at Screening;
- •Treatment with any intraarticular, intravenous, or intramuscular systemic corticosteroids within 14 days of Screening;
- •Treatment with oral prednisone > 10 mg per day or > 20 mg every other day (or equivalent dose of another corticosteroid) within 14 days of Screening;
- •Increased dose of systemic corticosteroids in the 14 days prior to Screening;
- •Treatment with cyclophosphamide or anti-TNFalpha biologic agents within 3 months before Visit 1 (Day 1);
- •Treatment with B cell-depleting monoclonal antibodies (rituximab, Ocrelizumab, anti-CD22) within 6 months before Visit 1 (Day 1);
- •Treatment with methotrexate, mycophenolate, azathioprine, leflunomide, cyclosporine, belimumab, tacrolimus, or any other immunosuppressive agent not included in 2b.-d. above, when the dose of that immunosuppressive agent has increased within 3 months before Visit
- •Concurrent treatment with any of these medications is allowed as long as the doses have been stable for at least 3 months before Visit 1 (Day 1); or
- •Actively listed on an organ transplantation list or have received an organ transplant other than a corneal transplant.
- •Significant diseases or conditions other than SLE that may influence response to the study product or safety, such as:
- •Active bacterial or viral infection requiring systemic antibiotic or anti-viral treatment within 14 days before Visit 1 (Day 1);
- •Acute or chronic hepatitis B or C infection;
- •Human immunodeficiency infection (HIV);
- •History of active tuberculosis or positive tuberculosis skin or blood test without: 1) completing a course of appropriate treatment; or ) having received at least one month of appropriate treatment prior to Visit 1 (Day 1) and continuing to receive appropriate treatment during the study;
- •No elective surgery should be planned from Visit 1 (Day 1) through Visit 6 (Day 112); or
- •A history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy greater than one year before Visit 1 (Day 1).
- •Significant heart disease as defined by:
- •Uncontrollable congestive heart failure, unstable angina, unstable atherosclerotic cardiovascular disease, significant arrhythmia requiring chronic therapy, pulmonary arterial hypertension with dyspnea, disability rated as New York heart Association Grade III or higher, severe systemic hypertension or severe peripheral vascular disease;
- •Marked baseline prolongation of QT/QTc interval (i.e. repeated demonstration of a QTc interval ≥ 450 msec for males and ≥470 msec for females);
- •History of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT/QTc syndrome); or
- •Clinically significant confirmed abnormality, as determined by the site investigator or qualified designee, on 12-lead Electrocardiogram (ECG) at Screening or Visit 1 (Day 1) before dosing.
- •History of chronic pain requiring treatment with narcotic analgesia for more than 14 days total within 6 months of baseline. This does not include self-limited pain associated with identifiable events such as surgery;
- •Current evidence of alcohol abuse (defined as 4 or more drinks per day on at least 4 days of the week) or history of abuse of illegal and/or legally prescribed drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, or opioids during the 1 year prior to Screening;
- •Currently pregnant, breast-feeding, or lactating;
- •Any investigational agent within 30 days or five therapeutic half-lives of that agent whichever is longer, before Visit 1 (Day 1);
- •Any of the following values for laboratory tests at Screening:
- •A positive pregnancy test (also at Visit 1);
- •A newly positive QuantiFERON(R) blood test for tuberculosis, without: 1) completing a course of appropriate treatment; or ) having received at least one month of appropriate treatment prior to Visit 1 and continuing to receive appropriate treatment during the study. If the subject has a previous documented positive tuberculosis skin, then this testing does not need to be repeated. If the subject has a documented negative test result within the last year, testing does not need to be repeated, at the discretion of the site investigator.
- •Hemoglobin < 8 g/dL;
- •Neutrophils < 1.0 x 10^9/L;
- •Platelets < 75 x 10^9/L;
- •Estimated Glomerular Filtration Rate (eGFR) < 50 ml/min according to Cockcroft-Gault equation;
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.0 x upper limit of normal; or
- •Total bilirubin ≥ 1.5 x upper limit of normal.
- •Any other conditions that, in the opinion of the site investigator, are clinically significant and may put the subject at greater safety risk, influence response to study product, or interfere with study assessments. When in doubt, the site investigator or qualified designee should discuss the situation with the Protocol Chairs.
研究组 & 干预措施
JBT-101: 20 mg & Placebo
Experimental
Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
干预措施: Placebo (Drug)
Placebo + Placebo
Placebo Comparator
Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
干预措施: Placebo (Drug)
JBT-101: 5 mg Twice Daily
Experimental
Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
干预措施: JBT-101 (Drug)
JBT-101: 20 mg & Placebo
Experimental
Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
干预措施: JBT-101 (Drug)
JBT-101: 20 mg Twice Daily
Experimental
Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
干预措施: JBT-101 (Drug)
结局指标
主要结局
Improvement in the Maximum Daily NRS-Pain Score at Day 84
时间窗: Day 1 through Day 84
The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as you can imagine). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. Participants will be asked to report their maximum daily pain using the NRS-Pain. Participants will call into an interactive voice response e diary system (IVRS) and record the number that best reflects their maximum amount of pain experienced in the last 24 hours. Participants will be asked to call at the same time each day, preferably before bedtime. Longitudinal trends over the course of the treatment period will be modeled and used to estimate difference between means at baseline and Day 84 for each treatment group.
次要结局
- Percentage of Participants Who Had at Least 30% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Percentage of Participants Who Had at Least 50% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Change From Baseline in Physician Assessed Swollen Joint Count(Baseline, (Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change From Baseline in the Improvement Pain Category Prior to Study Visits(Visit 6 (Day 113))
- Percentage of Participants Who Had at Least 75% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Change From Baseline in Physician Assessed Tender Joint Count(Baseline, (Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)
- Percentage of Participants With Presence of Arthritis in SELENA-SLEDAI(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Change in Baseline in PROMIS-29 Short Form Score - Physical Function T-score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment))
- Change in Baseline in PROMIS - Fatigue T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Number of Participants With No Pain, Mild Pain, Moderate Pain or Severe Pain in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 6 (Day 113))
- Change in Baseline in PROMIS - Pain Intensity(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Percentage of Participants as Responders Using the SLE Responder Index (SRI)(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Change From Baseline in Lupus Disease Activity - Total BILAG-2004 Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change From Baseline in Lupus Disease Activity -Physician's Global Assessment (PGA) Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change From Baseline in Lupus Disease Activity- Patient Global Assessment Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Percentage of Participants Who Had 100% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Percentage of Participants With Improvement From Baseline in Arthritis in BILAG-2004(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113))
- Change in Baseline in PROMIS - Anxiety T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change in Baseline in PROMIS - Depression T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change in Baseline in PROMIS Cognitive Function T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Percentage of Participants Indicating Clinical Benefit in Treatment Satisfaction(Visit 5 (Day 85 - Last Day of Treatment))
- Change From Baseline in Lupus Disease Activity - SELENA-SLEDAI Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change in Baseline in PROMIS - Sleep Disturbance T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Change in Baseline in PROMIS - Pain Interference T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Number of Grade 3 or Higher Treatment-emergent Adverse Events (TEAE) Related to Study Product(Day 1 after initiation of study intervention through Day 113)
- Number of BILAG-2004 Disease Flares(Visit 6 (Day 113))
- Change in Baseline in PROMIS - Social Role Satisfaction T-Score(Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment))
- Number of Treatment Emergent Events With Elevated Liver Tests(Day 1 through Visit 6 (Day 113))
- Percentage of Physicians Indicating Participant Clinical Benefit in Treatment Satisfaction(Visit 5 (Day 85 - Last Day of Treatment))
- Number of Treatment Emergent QTc Prolongation Events(Visit 1 (Baseline, Day 1) and Visit 5 (Day 85 - Last Day of Treatment))
- Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)(Visit 6 (Day 113))
- Percentage of Participants With Increased Scores From Baseline on ARCI-M(Visit 1 (Baseline, Day 1-prior to treatment initiation), Visit 1 (Baseline, Day 1-post-treatment initiation) Visit 3 (Day 29) and Visit 5 (Day 85 - Last Day of Treatment))
- Number of Treatment Emergent Intolerability Events(Day 1 after initiation of study intervention through Visit 5 (Day 85 - Last Day of Treatment))
- Number of Participants With No Pain, Mild Pain, Moderate Pain or Severe Pain in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 1 (Baseline))
- Number of Participants With No Pain, Mild Pain, Moderate Pain or Severe Pain in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 3 (Day 29))
- Number of Participants With No Pain, Mild Pain, Moderate Pain or Severe Pain in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 4 (Day 57))
- Number of Participants With No Pain, Mild Pain, Moderate Pain or Severe Pain in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits(Visit 5 (Day 85))
- Change From Baseline in the Improvement Pain Category Prior to Study Visits(Visit 3 (Day 29))
- Change From Baseline in the Improvement Pain Category Prior to Study Visits(Visit 4 (Day 57))
- Change From Baseline in the Improvement Pain Category Prior to Study Visits(Visit 5 (Day 85))
- Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)(Visit 3 (Day 29))
- Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)(Visit 4 (Day 57))
- Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)(Visit 5 (Day 85))
- Number of BILAG-2004 Disease Flares(Visit 3 (Day 29))
- Number of BILAG-2004 Disease Flares(Visit 4 (Day 57))
- Number of BILAG-2004 Disease Flares(Visit 5 (Day 85))
研究者
研究点 (30)
Loading locations...
相似试验
终止
2 期
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With DermatomyositisDermatomyositisNCT02466243Corbus Pharmaceuticals Inc.22
已完成
2 期
BTRX-246040 Study in Participants With Parkinson's Disease With Motor FluctuationsMotor DisorderParkinson DiseaseNCT03608371BlackThorn Therapeutics, Inc.24
已完成
1 期
Safety Study of RMJH-111b to Treat Essential HypertensionEssential HypertensionNCT02822222RMJ Holdings, LLC22
已完成
2 期
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious DistressDepressive DisorderAnxietyNCT02498392Janssen Research & Development, LLC161
撤回
2 期
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled AsthmaAsthmaNCT01493882Johnson & Johnson Pharmaceutical Research & Development, L.L.C.